Teva announces presentation of survey study on TEV-‘749

Teva (TEVA) Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries, announced the presentation of a patient and healthcare professional (HCP) attitudes and experiences survey study, complementing the successful Phase 3 Subcutaneous Olanzapine Extended-Release Injection Study evaluating TEV-‘749. More than 92% of patients, 87% of nurses and 72% of physicians were either satisfied or very satisfied when asked about TEV-‘749, overall, including initiation regimen, monthly dosing schedule and dosing options. The data were presented at the 2025 Congress of the Schizophrenia International Research Society taking place from March 29 to April 2 in Chicago. “Schizophrenia is an incredibly complex condition with profound impacts on mental health and daily life. That’s why understanding the treatment perspectives of patients and healthcare providers is integral to Teva’s research, and these survey results underscore the personal approach we’ve taken with the development of TEV-‘749,” said Eric Hughes, MD, PhD, Executive Vice President, Global R&D and Chief Medical Officer at Teva. “This early clinical feedback on TEV-‘749 is encouraging across some of the most important schizophrenia treatment factors – dosing schedule, initiation regimen, subcutaneous administration, post-injection monitoring requirements and general satisfaction.”